Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

被引：0
|
作者：
Dimopoulos, Meletios A. [1 ]
Terpos, Evangelos [1 ]
Gavriatopoulou, Maria [1 ]
Kalapanida, Despoina [1 ]
Eleutherakis-Papaiakovou, Evangelos [1 ]
Roussou, Maria [1 ]
Mparmparoussi, Despoina [2 ]
Zomas, Athanasios [3 ]
Gika, Dimitra [1 ]
Kartasis, Zafiris [4 ]
Matsouka, Charis [2 ]
Kostis, Evangelos [1 ]
Kontogiannis, Sofoklis [1 ]
Konstantopoulos, Kostas [1 ]
Kastritis, Efstathios [1 ]
机构：
[1] Univ Athens, Sch Med, Athens 11528, Greece
[2] Alexandra Gen Hosp, Athens, Greece
[3] St Anargiri Canc Hosp, Athens, Greece
[4] Gen Hosp Chalkida, Chalkida, Greece
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Multiple myeloma - in-vitro studies of new compounds with potential anti-myeloma activity
    Steiner, N.
    Kern, J.
    Untergasser, G.
    Willenbacher, W.
    Gastl, G.
    Gunsilius, E.
    ONKOLOGIE, 2013, 36 : 148 - 149
  • [42] Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study
    Campbell, John P.
    Heaney, Jennifer L. J.
    Pandya, Sankalp
    Afzal, Zaheer
    Kaiser, Martin
    Owen, Roger
    Child, J. Anthony
    Cairns, David A.
    Gregory, Walter
    Morgan, Gareth J.
    Jackson, Graham H.
    Bunce, Chris M.
    Drayson, Mark T.
    LANCET HAEMATOLOGY, 2017, 4 (12): : E584 - E594
  • [43] Avicins: A novel class of anti-myeloma agents.
    Mitsiades, N
    McMullan, CJ
    Poulabi, V
    Negri, J
    Geer, DC
    Haridas, V
    Munshi, NC
    Gutterman, J
    Anderson, KC
    Mitsiades, CS
    BLOOD, 2004, 104 (11) : 929A - 929A
  • [44] HUMAN HERPESVIRUS 6 IS A FREQUENT INFECTION IN MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL ANTI-MYELOMA AGENTS
    Horowitz, N.
    Lavi, N.
    Zuckerman, T.
    Benyamini, N.
    Oren, I.
    Kra-Oz, Z.
    Held, V.
    Avivi, I.
    HAEMATOLOGICA, 2012, 97 : 397 - 397
  • [45] CHARACTERIZATION OF A PERK KINASE INHIBITOR WITH ANTI-MYELOMA ACTIVITY
    Bagratuni, T.
    Kastritis, E.
    Mavrianou, N.
    Liacos, C.
    Terpos, E.
    Dimopoulos, M.
    HAEMATOLOGICA, 2016, 101 : 512 - 512
  • [46] CRYAGLUTININE DISEASE OF IGA SUBTYPE AS EARLY MANIFESTATION OF MULTIPLE MYELOMA AND RESOLUTION AFTER TREATMENT WITH NEW ANTI-MYELOMA DRUGS
    Acevedo Carolina, Chic
    Torres Estefania, Garcia
    Miguel Angel, Alvarez Rivas
    HAEMATOLOGICA, 2016, 101 : 308 - 309
  • [47] Dissecting The Potential Role Of Prevnar As An Anti-Myeloma Vaccine
    Noonan, Kimberly
    Rudraraju, Lakshmi
    Ferguson, Anna
    Sidorski, Amy
    Casildo, Andrea
    Griffin, Ervin
    Lee, Susan
    Ghosh, Nilanjan
    Matsui, William
    Huff, Carol
    Borrello, Ivan M.
    BLOOD, 2013, 122 (21)
  • [48] Venetoclax: the first anti-myeloma agent with a reliable biomarker
    Jelinek, Tomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) : 1003 - 1005
  • [49] Emerging of valproic acid as an anti-myeloma agent.
    Kitazoe, Kenichi
    Abe, Masahiro
    Choraku, Masahito
    Kagawa, Kumiko
    Asano, Jin
    Takeuchi, Kyoko
    Hiasa, Masahiro
    Hashimoto, Toshihiro
    Ozaki, Shuji
    Oda, Asuka
    Amou, Hiroe
    Matsumoto, Toshio
    BLOOD, 2006, 108 (11) : 993A - 993A
  • [50] Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
    Bagratuni, Tina
    Patseas, Dimitrios
    Mavrianou-Koutsoukou, Nefeli
    Liacos, Christine Ivy
    Sklirou, Aimilia D.
    Rousakis, Pantelis
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Tsitsilonis, Ourania E.
    Trougakos, Ioannis P.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    CANCERS, 2020, 12 (10) : 1 - 20
12345